Medical Science Liaison - Oncology, Lake Michigan Region

United States

Apply with AI Apply

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, Pharmaceuticals, BiotechnologyIndustries

Requirements

Candidates should possess an advanced healthcare or scientific degree, such as a Ph.D., Pharm.D., M.D., or D.N.P., with a Master’s degree being required. Previous Medical Science Liaison experience is preferred, though not mandatory, and the candidate must reside within the specified Lake Michigan region.

Responsibilities

The Medical Science Liaison – Oncology will provide scientific and clinical presentations on Natera’s oncology products, serve as a medical and scientific resource for various internal teams, establish and maintain relationships with Key Opinion Leaders and Healthcare Providers, collaborate with lab operations, represent Natera at scientific congresses, engage in continuous learning, provide medical expertise for materials and publications, support clinical trial initiatives, and travel extensively (over 60%) as needed, while also performing other assigned duties.

Skills

Scientific Presentation

Relationship Building

Key Opinion Leader Engagement

Clinical Trial Support

Scientific Communication

Healthcare Provider Collaboration

Travel Readiness

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free